Clinical Trial Update: LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating LMP1- and LMP2-specific cytotoxic T lymphocytes for EBV-positive nasopharyngeal carcinoma (NATELLA) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• LMP1- and LMP2-specific cytotoxic T lymphocytes

Snippet

Sponsor: Baylor College of Medicine | Conditions: Nasopharyngeal Carcinoma | Phase 1 | Status: COMPLETED